BMY - Better Buy: Biogen vs. Celgene
Biogen (NASDAQ: BIIB) and Celgene (NASDAQ: CELG) claimed similar market caps earlier this year. That's not the case now, though. In March, Biogen announced that it was halting late-stage clinical studies for its once-promising Alzheimer's disease drug, aducanumab. The biotech's shares collapsed. Celgene's market cap now stands well above Biogen's.
But with Celgene months away from being gobbled up by Bristol-Myers Squibb (NYSE: BMY) and Biogen's valuation taking a shellacking, which of these two biotech stocks is the better pick for investors now? Here's how the companies compare in three key areas.
Image source: Getty Images.